Japan ' s Astellas to Buy Audentes for $3 Bln in High-Priced Gene Therapy Bet Japan ' s Astellas to Buy Audentes for $3 Bln in High-Priced Gene Therapy Bet
Japan ' s Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news
More News: Allergy | Allergy & Immunology | Gene Therapy | Genetics | Japan Health | Pharmaceuticals | Primary Care